Altimmune, Inc. (ALT) Dividend History

Company News

• Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?

  Pfizer's experimental obesity drug danuglipron failed due to safety concerns, leading the company to consider acquiring Altimmune or Viking Therapeutics, which have promising obesity drug candidates. Pfizer may wait to see how its other obesity drug, PF-07976016, performs in clinical trials before making an acquisition decision.

  The Motley Fool

  Featured Companies: PFE VKTX
• Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

  The article discusses three undervalued stocks that could be great investments: Altimmune, Moderna, and Pfizer. Altimmune is a high-risk, high-potential-reward play on its weight loss drug candidate. Moderna's stock has fallen significantly, but the company's mRNA platform and pipeline hold promise. Pfizer's low valuation and strong growth prospects make it an attractive option.

  The Motley Fool

  Featured Companies: MRNA PFE
• Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight

  The obesity market is projected to grow from 2024 to 2034 due to the rising prevalence of obesity and the extensive pipeline of emerging drugs with improved safety profiles. The article discusses different types of obesity, including hypothalamic, pediatric, POMC deficiency, and syndromic/monogenic obesity, and the current treatment landscape and pipeline for each.

  GlobeNewswire Inc.

  Featured Companies: AARD LLY PFE RYTM SLNO
• Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

  Johnson Fistel, LLP is conducting an investigation into potential securities law violations by certain officers at Sprout Social, Altimmune, Equinix, and Globe Life. The firm is considering initiating derivative lawsuits on behalf of long-term investors in these companies.

  GlobeNewswire Inc.

  Featured Companies: EQIX GL SPT
• Why Altimmune Was Such a Robustly Healthy Stock on Thursday

  Altimmune, a biotech company, announced that it will be added to the Nasdaq Biotechnology Index, which is seen as an important recognition for the company's progress, particularly with its investigational drug pemvidutide for obesity.

  The Motley Fool